GO:0004614 phosphoglucomutase activity explained

Phosphoglucomutase activity (GO:0004614) is a molecular function that catalyzes the reversible transfer of a phosphate group between the C1 and C6 positions of glucose, interconverting glucose-1-phosphate (G1P) and glucose-6-phosphate (G6P). This reaction sits at a metabolic crossroads: G1P is the activated sugar used for glycogen synthesis and for building UDP-glucose, while G6P feeds glycolysis and the pentose phosphate pathway. Because the reaction is freely reversible, the direction of flux depends on cellular demand and on the activity state of the enzyme. The enzyme carrying this activity, phosphoglucomutase 1 (PGM1), is regulated by phosphorylation, and this regulatory phosphorylation event tunes its activity to regulate glycogen metabolism. A signaling kinase can also regulate PGM1 phosphorylation and activity, connecting this metabolic step to signal transduction. Beyond glucose homeostasis, phosphoglucomutase activity supplies precursors for glycosylation. The PGM3 isoform contributes to hexosamine synthesis, and PGM3 insufficiency produces a glycosylation disorder with a prominent T cell defect. In cancer, phosphoglucomutase activity can be reprogrammed: PGM3 targeting abolishes SREBP-1 activation and hexosamine synthesis feedback to suppress brain tumor growth, and cancer-associated fibroblasts secrete CSF3 to promote triple-negative breast cancer progression by enhancing PGM2L1-dependent glycolysis reprogramming. These findings place GO:0004614 at the interface of metabolism, immunity, and oncology. For researchers, GO:0004614 is a tractable entry point to study metabolic flux, glycosylation capacity, and disease mechanisms. The activity can be modulated by metal ion balance, as shown by the influence of the cellular Mn/Zn ratio on phosphoglucomutase activity and capsule production in Streptococcus pneumoniae. It is also a pharmacological readout: erythrocyte phosphoglucomutase activity has been compared in bipolar I patients taking lithium or carbamazepine, and lithium induces phosphoglucomutase activity in various rat tissues and in bipolar patients. This article summarizes the definition, mechanism, key genes, disease links, and experimental methods for studying GO:0004614.

GO:0004614 phosphoglucomutase activity is the catalytic function that reversibly converts glucose-1-phosphate to glucose-6-phosphate (and the reverse reaction) through a phosphoenzyme intermediate. In practical terms, it is the enzymatic step that lets a cell move phosphate between the 1 and 6 positions of glucose, thereby channeling sugar phosphates into glycogen synthesis, glycolysis, or glycosylation precursor pools. The activity is carried by phosphoglucomutase enzymes such as PGM1, and its output is adjusted by regulatory phosphorylation and by signaling kinases. Because the reaction is reversible, the net direction depends on substrate availability and on the enzyme's regulatory state rather than on an irreversible committed step.

Phosphoglucomutase activity is important because it controls the reversible exchange between glucose-1-phosphate and glucose-6-phosphate, a node that determines whether glucose is stored as glycogen, burned through glycolysis, or used to build glycosylation precursors. This makes GO:0004614 relevant to energy metabolism, protein glycosylation, immune cell function, and cancer biology. The activity is not static: it is tuned by regulatory phosphorylation and by signaling kinases, and it responds to metal ion balance. Clinically, phosphoglucomutase activity has been measured in bipolar disorder patients on lithium or carbamazepine, and lithium itself induces the activity in rat tissues and patients. In cancer, PGM3 and PGM2L1 support tumor growth and microenvironment-driven progression [7,8], while PGM3 insufficiency causes a glycosylation disorder with a T cell defect. Together, these findings make GO:0004614 a high-value target for metabolic, immunological, and oncological research.

The following genes and proteins are directly implicated in phosphoglucomutase activity (GO:0004614) or in its regulation and disease relevance, based on the verified literature.

Phosphoglucomutase activity is regulated at multiple levels. A regulatory phosphorylation event on PGM1 tunes its activity to regulate glycogen metabolism, meaning the enzyme's phosphorylation state adjusts flux through the glucose-1-phosphate/glucose-6-phosphate node. A signaling kinase can regulate PGM1 phosphorylation and activity, connecting this metabolic step to upstream signal transduction. Metal ion balance also matters: the cellular Mn/Zn ratio influences phosphoglucomutase activity and capsule production in Streptococcus pneumoniae D39. Pharmacologically, lithium induces phosphoglucomutase activity in various rat tissues and in bipolar patients, and erythrocyte phosphoglucomutase activity has been measured in bipolar I patients using lithium or carbamazepine. In cancer, PGM3-dependent hexosamine synthesis feedback regulates SREBP-1 activation, and PGM2L1-dependent glycolysis reprogramming in cancer-associated fibroblasts is driven by CSF3 secretion. Together, these mechanisms show that phosphoglucomutase activity is dynamically controlled by phosphorylation, signaling kinases, metal ions, and pharmacological agents.

PGM3 insufficiency is a glycosylation disorder causing a notable T cell defect. Because PGM3 supports hexosamine synthesis and glycosylation, reduced phosphoglucomutase activity in this pathway impairs protein glycosylation and immune cell function. This links GO:0004614 to congenital disorders of glycosylation and immunodeficiency research.

Targeting PGM3 abolishes SREBP-1 activation and hexosamine synthesis feedback regulation to effectively suppress brain tumor growth. This suggests that phosphoglucomutase activity in the hexosamine pathway supports lipid metabolic reprogramming in brain tumors, making PGM3 a potential therapeutic target.

Cancer-associated fibroblasts secrete CSF3 to promote triple-negative breast cancer progression via enhancing PGM2L1-dependent glycolysis reprogramming. This identifies PGM2L1-driven phosphoglucomutase activity as a stroma-supported metabolic vulnerability in TNBC.

Erythrocyte phosphoglucomutase activity has been studied in bipolar I patients currently using lithium or carbamazepine, and lithium induces phosphoglucomutase activity in various tissues of rats and in bipolar patients. These findings suggest phosphoglucomutase activity may serve as a peripheral marker of mood-stabilizer action, though the clinical implications require further study [4,6].

Phosphoglucomutase activity can be measured directly in cell or tissue lysates by coupling the interconversion of glucose-1-phosphate and glucose-6-phosphate to NADPH production or other readouts. Erythrocyte phosphoglucomutase activity has been measured in bipolar I patients using lithium or carbamazepine, and tissue activity has been assessed in rats and patients after lithium treatment. These assays provide a direct functional readout of GO:0004614.

Because PGM1 activity is tuned by regulatory phosphorylation and by a signaling kinase, phospho-specific antibodies and kinase inhibitor studies can reveal how upstream signals modify phosphoglucomutase activity. Combining phosphoproteomics with activity assays helps establish causal links between phosphorylation events and flux through the glucose-1-phosphate/glucose-6-phosphate node [1,3].

Stable isotope tracing and metabolomics can quantify how phosphoglucomutase activity affects glycogen, glycolysis, and hexosamine synthesis. Glycosylation profiling is particularly relevant for PGM3, where insufficiency causes a glycosylation disorder with T cell defect, and for brain tumor studies where PGM3 targeting disrupts SREBP-1 activation and hexosamine synthesis feedback.

In triple-negative breast cancer, cancer-associated fibroblasts secrete CSF3 to promote progression via PGM2L1-dependent glycolysis reprogramming. Co-culture systems, cytokine neutralization, and glycolysis flux measurements can dissect how stromal signals regulate phosphoglucomutase activity in tumors.

Researchers studying phosphoglucomutase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic flux, glycosylation, or disease progression. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point mutation, knock-in, and overexpression of genes such as PGM1, PGM3, and PGM2L1, along with library screening and bioinformatics support to accelerate discovery.

GO:0004614 phosphoglucomutase activity is a central enzymatic function that reversibly interconverts glucose-1-phosphate and glucose-6-phosphate, influencing glycogen metabolism, glycolysis, and glycosylation. Its activity is regulated by phosphorylation [1,3], metal ion balance, and pharmacological agents such as lithium [4,6]. Disease links span glycosylation disorders with T cell defects, brain tumors, and triple-negative breast cancer, making it a compelling target for metabolic, immunological, and oncological research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide powerful tools to dissect the causal roles of PGM1, PGM3, and PGM2L1 in these contexts [1,5,7,8].